Third Wave this week reported a 25-percent increase in its third-quarter molecular diagnostic revenue, and said it will focus on penetrating the high-risk human papillomavirus diagnostics space and the broader hospital-testing market with a single test for HPV, chlamydia/gonorrhea, and hospital-acquired infections.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.